Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

Publication

Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression.

Chelsea R Tieszen | Alicia A Goyeneche | BreeAnn N Brandhagen | Casey T Ortbahn | Carlos M Telleria
BMC cancer | 2011

Mifepristone (MF) has been largely used in reproductive medicine due to its capacity to modulate the progesterone receptor (PR). The study of MF has been expanded to the field of oncology; yet it remains unclear whether the expression of PR is required for MF to act as an anti-cancer agent. Our laboratory has shown that MF is a potent inhibitor of ovarian cancer cell growth. In this study we questioned whether the growth inhibitory properties of MF observed in ovarian cancer cells would translate to other cancers of reproductive and non-reproductive origin and, importantly, whether its efficacy is related to the expression of cognate PR.

Pubmed ID: 21619605

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: NCI NIH HHS, United States
    Id: K22CA121991
  • Agency: NCI NIH HHS, United States
    Id: K22CA121991-S1
  • Agency: NCRR NIH HHS, United States
    Id: P20 RR-015567

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.

SaOS-2 (tool)

RRID:CVCL_0548

Cell line SaOS-2 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

MCF-7 (tool)

RRID:CVCL_0031

Cell line MCF-7 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

U2OS (tool)

RRID:CVCL_0042

Cell line U2OS is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

PC-3 (tool)

RRID:CVCL_0035

Cell line PC-3 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

MDA-MB-231 (tool)

RRID:CVCL_0062

Cell line MDA-MB-231 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

U-87MG ATCC (tool)

RRID:CVCL_0022

Cell line U-87MG ATCC is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

SK-OV-3 (tool)

RRID:CVCL_0532

Cell line SK-OV-3 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

OVCAR-3 (tool)

RRID:CVCL_0465

Cell line OVCAR-3 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

About

The Stimulating Peripheral Activity to Relieve Conditions (SPARC) effort is the result of National Institutes of Health’s (NIH) drive to map out the neural circuitry responsible for visceral control in higher vertebrates. The SPARC Anatomy Working Group (SAWG) is responsible for the integrity of anatomical knowledge in SPARC

Recent News Entries

Contact Us

Maryann Martone, Ph.D.

Department of Neurosciences, School of Medicine

University of California, San Diego

About SciCrunch | Privacy Policy | Terms of Service

SciCrunch